A urologist weighs in on whether biking can cause prostate issues or erection problems. The science-based answer is that the ...

Cancer of the prostate has become the leading cause of cancer diagnoses among males in the United Kingdom. Its treatment, ...

A leading doctor has answered several common questions about prostate cancer in an effort to separate facts from fiction. His ...

Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...

Prostate cancer is still associated with fear and social stigma, despite being the second most common cancer among men and one that needs attention. A urologist explained that advances in treatment ...

I was one in eight. One in eight men will be diagnosed with prostate cancer in their lifetime. Nah, I was one in six. One in ...

As of Tuesday morning, Corcept Therapeutics shares are down by 0.59%, with a current price of $79.35. This implies that ...

Terminally ill cycling star Sir Chris Hoy has revealed that there was one key sign of cancer he brushed off as 'just getting old'. Speaking in an hour-long documentary, Sir Chris Hoy: Cancer, Courage ...

Six time Olympic champion Sir Chris Hoy has shared an emotional detail about the journey of his terminal illness. In an ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

Sir Chris Hoy’s stage-four diagnosis has put prostate cancer under the spotlight among cyclists. Cycling Weekly tackles the confusion around risk factors and screening ...

During Tuesday's morning session, Corcept Therapeutics shares down by 0.59%, currently priced at $79.35. Considering the current price, Robb's 145,000 shares have a total value of $10,963,450.